Abstract:

To explore the effect of doxorubicin on lncRNAs in canine breast tumor cells and find potential biomarkers and therapeutic targets for canine mammary tumor, RNA-Seq technology was used to perform transcriptome sequencing analysis on canine breast tumor cells treated with doxorubicin, and differentially expressed lncRNAs were screened. GO enrichment and KEGG enrichment analysis were used to annotate gene functions and pathways and verify their expression. The results showed that there were 277 differentially expressed lncRNAs in canine breast tumor cells after doxorubicin treatment, of which 147 were up-regulated and 130 were down-regulated, mainly involving biological processes such as cell metabolism, transcriptional program disorder, ECM receptor interaction and cell necroptosis. Three differentially expressed lncRNAs were randomly detected by real-time quantitative PCR, and their expression trends were consistent with RNA-Seq, indicating the accuracy of the RNA-Seq sequencing results. Based on transcriptomics technology, this study comprehensively analyzed the overall characteristics of the expression changes of lncRNAs related to doxorubicin against canine breast tumor cells, revealed its possible new regulatory mechanisms, and provided a reference for the targeted therapy of canine mammary tumor and the development and utilization of potential biomarkers.

Key words: lncRNA, canine, mammary tumor cells, doxorubicin, RNA-Seq